Scleroderma Treatment Market

Scleroderma Treatment Market Overview

The global scleroderma treatment market was valued at US$ 1.46 Billion in 2021, expected to expand at a Y-o-Y rate of 4.8% to reach US$ 1.53 Billion in FY 2022. Across the 2022-2032 assessment period, sales ae expected to flourish at a CAGR of 5.45% to reach US$ 2.6 Billion.

Scleroderma refers to a group of autoimmune diseases that cause changes in blood vessels, skin, muscles, and other organs. Scleroderma symptoms include thickened and stiff skin, lethargy, and decreased blood flow to extremities of the limbs such as fingers and toes when exposed to cold. Scleroderma can also cause calcium deposits, Raynaud's syndrome, and esophageal problems.

Which are Some Prominent Drivers Spearheading Scleroderma Treatment Market Growth?

Scleroderma's rising incidence and screening rates are the primary drivers of the Scleroderma market. The prevalence of Scleroderma in the United States is 240 per million, with an annual incidence of 19 per million, indicating a significant unmet need. The prevalence of Scleroderma in Europe is estimated to be between 10 and 150 per million people, with an annual incidence of 3 to 28 per million people.

The rising risk of exposure to risk factors such as silica, aromatic and chlorinated solvents, ketones, welding fumes, and the development of advanced high sensitive and selective skin biopsy and blood tests is propelling the market growth.

Why is Europe Emerging as an Opportunistic Scleroderma Treatment Market?

Germany and France are expected to lead the scleroderma Treatment markets in Europe. Europe has a lower market share than North America, owing to the use of biosimilars and generics for off-label treatment of systemic scleroderma. The systemic scleroderma treatment market in the United Kingdom is expected to grow significantly in the coming years. This is primarily due to the introduction of biologics and small molecules for the treatment of systemic sclerosis and related indications.

How is North America Contributing to Growth of the Scleroderma Treatment Market?

North America is expected to account for the largest share of the global Scleroderma treatment market due to rising female income, large investments by pharmaceutical companies, and the market's enormous potential. Furthermore, increasing novel product approvals are expected to drive market growth over the forecast period.

 For example, Kadmon Holdings, Inc., a pharmaceutical company based in the United States, received orphan drug designation from the United States Food and Drug Administration (FDA) in September 2020 for its potential drug candidate belumosudil. Belumosudil is a Rho-associated coiled kinase inhibitor that can be used to treat rare diseases such as systemic scleroderma.

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

Market Competition

Some of the major players in the global Scleroderma Treatment market are Cumberland Pharmaceuticals, Inc., Gilead Sciences, Inc., Pfizer, Inc., Sanofi, Boehringer Ingelheim International GmbH, Corbus Pharmaceuticals Holdings, Inc. and Actelion Pharmaceuticals, Inc.

Report Scope

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Sign-Up

Key Segments Profiled in the Scleroderma Treatment Industry Survey

 By Drug Class:

• Anti-Inflammatory Scleroderma Treatment Agents
• Immunosuppressive Scleroderma Treatment Agents
• Vascular Scleroderma Treatment Agents
• Anti-Fibrotic Scleroderma Treatment Agents
• Other Scleroderma Treatment Drugs

By Type:

• Localized Scleroderma Treatment
• Systemic Scleroderma Treatment

By Distribution Channel:

• Institutional Sales of Scleroderma Treatment Drugs
• Retail Sales of Scleroderma Treatment Drugs
• Online Sales of Scleroderma Treatment Drugs

By Region:

• North America
• Latin America
• Europe
• CIS & Russia
• Japan
• APEJ
• Middle East and Africa